Clinical evaluation of tau-imaging PET tracer [18F]THK-5351 in dementia

Clinical evaluation of tau-imaging PET tracer [18F]THK-5351 in dementia - Clinical evaluation of [18F]THK-5351 in dementia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000043737

Enrollment

210

Registered

2021-03-25

Start date

2021-03-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild cognitive impairment, Alzheimer&#39

Interventions

[18F]THK-5351 PET or PET/CT studies will be performed in the patients and healthy volunteers. PET images of the brain will be acquired for 90 min after intravenous injection of 2-5 MBq/kg [18F]THK-535

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) mild cognitive impairment, Alzheimer's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia, dementia with Lewy bodies and Parkinson's disease 2) 20 years of age or older at the time of obtaining consent

Exclusion criteria

Exclusion criteria: 1) Pregnant, possibly pregnant or lactating women 2) Subject who is facing a life crisis 3) Subject who was judged by the investigator to be inappropriate as a participant in this study

Design outcomes

Primary

Measure	Time frame
Distribution of tau-imaging PET tracer [18F]THK-5351	—

Countries

Japan

Contacts

Public ContactYuka Yamamoto

Faculty of Medicine, Kagawa University Department of Radiology

yuka@med.kagawa-u.ac.jp087-898-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026